2647 related articles for article (PubMed ID: 19903804)
1. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
2. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
[TBL] [Abstract][Full Text] [Related]
4. Re: Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Lynge E; Rebolj M
J Natl Cancer Inst; 2010 May; 102(10):739; author reply 739-40. PubMed ID: 20360534
[No Abstract] [Full Text] [Related]
5. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
7. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
8. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
9. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening.
Kotaniemi-Talonen L; Malila N; Nieminen P; Anttila A; Tarkkanen J; Laurila P; Hakama M
Int J Cancer; 2008 Dec; 123(12):2902-6. PubMed ID: 18792100
[TBL] [Abstract][Full Text] [Related]
10. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
13. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
14. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; De Marco L; Giorgi-Rossi P; Pontenani G; Rosso S; Sani C; Sintoni C; Segnan N; Zorzi M; Cuzick J; Rizzolo R; Ronco G;
Lancet Oncol; 2008 Oct; 9(10):937-45. PubMed ID: 18783988
[TBL] [Abstract][Full Text] [Related]
15. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
[TBL] [Abstract][Full Text] [Related]
16. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial.
Bergeron C; Giorgi-Rossi P; Cas F; Schiboni ML; Ghiringhello B; Dalla Palma P; Minucci D; Rosso S; Zorzi M; Naldoni C; Segnan N; Confortini M; Ronco G
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25568167
[TBL] [Abstract][Full Text] [Related]
17. HPV testing with cytology triage for cervical cancer screening in routine practice.
Louvanto K; Chevarie-Davis M; Ramanakumar AV; Franco EL; Ferenczy A
Am J Obstet Gynecol; 2014 May; 210(5):474.e1-7. PubMed ID: 24373948
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
19. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
[TBL] [Abstract][Full Text] [Related]
20. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
